ODTX news

Odyssey iteratively updated its stock presentation and trading symbols. Market relevance: Indicates operational status while disclaimers highlight uncertainties regarding current product candidate efficacy and clinical potential.

Odyssey Therapeutics, Inc. issued a corporate presentation outlining business strategy and future clinical developments. This update provides investors with insights into the company's developmental pipeline and regulatory outlook.

Odyssey Therapeutics reported positive clinical proof-of-concept data for OD-001, its oral RIPK2 inhibitor, showing 27% clinical remission and 61% clinical response in moderate-to-severe ulcerative colitis patients. The company closed a $314.8M IPO and has $464M in cash expected to fund operations i…